deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT03226574

Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for Treatment of Intractable Cancer Pain

A Multicenter, Open-Label, Phase 1b Study to Assess the Safety and Define the Maximally Tolerated Dose of Epidural Resiniferatoxin Injection for the Treatment of Intractable Pain Associated With Cancer

Sponsor: Sorrento Therapeutics, Inc.

Conditions Intractable Cancer Pain
Interventions Resiniferatoxin
Updated 19 times since 2017 Last updated: Oct 19, 2020 Started: Sep 1, 2017 Primary completion: Mar 18, 2020 Completion: Jun 18, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03226574, this PHASE1 trial focuses on Intractable Cancer Pain and remains completed. Sponsored by Sorrento Therapeutics, Inc., it has been updated 19 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Nov 2017 · 2 months · monthly snapshot~Nov 2017 – ~Mar 2018 · 4 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Nov 2018 · 4 months · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Mar 2019 · 59 days · monthly snapshot~Mar 2019 – ~Aug 2019 · 5 months · monthly snapshot~Aug 2019 – ~Oct 2019 · 2 months · monthly snapshot~Oct 2019 – ~Dec 2019 · 2 months · monthly snapshot~Dec 2019 – ~Apr 2020 · 4 months · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Nov 2020 · 6 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Nov 2020 — Jan 2021 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  5. May 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE1

▶ Show 14 earlier versions

  1. Apr 2020 — May 2020 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  2. Dec 2019 — Apr 2020 [monthly]

    Recruiting PHASE1

  3. Oct 2019 — Dec 2019 [monthly]

    Recruiting PHASE1

  4. Aug 2019 — Oct 2019 [monthly]

    Recruiting PHASE1

  5. Mar 2019 — Aug 2019 [monthly]

    Recruiting PHASE1

  6. Jan 2019 — Mar 2019 [monthly]

    Recruiting PHASE1

  7. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE1

  8. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE1

  9. Jul 2018 — Nov 2018 [monthly]

    Recruiting PHASE1

  10. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE1

  11. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

  12. Nov 2017 — Mar 2018 [monthly]

    Recruiting PHASE1

  13. Sep 2017 — Nov 2017 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  14. Aug 2017 — Sep 2017 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sorrento Therapeutics, Inc.
Data source: Sorrento Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations